Literature DB >> 11916178

Prevalence of human immunodeficiency virus, hepatitis B and hepatitis C virus antibodies and hepatitis B antigen among commercial sex workers in Japan.

K Ishi1, F Suzuku, A Saito, S Yoshimoto, T Kubota.   

Abstract

OBJECTIVE: To investigate the prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and of hepatitis B surface (HBs) antigen in commercial sex workers (CSW) who attended a sexually transmitted disease (STD) clinic in Tokyo.
METHODS: Surveys were conducted on 308 CSW and 384 control subjects for HIV antibody or 241 control subjects for HBs antibody and antigen and HCV antibody.
RESULTS: HIV antibody was not detected in either CSW or control subjects. The positive rates for HBs antigen and antibody were 0.6 and 23.4%, respectively, in the CSW group, and 0.4 and 71.8% in the control group. The HCV antibody positive rate was 3.2% in the CSW group and 0.4% in the control group.
CONCLUSION: A statistically significant difference between the two groups was observed only in HCV antibody positive rate. STD checkup for CSW alone is inadequate--STD health education and screening for the general public are also required.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11916178      PMCID: PMC1784653          DOI: 10.1155/S1064744901000357

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  11 in total

1.  [Epidemiology of hepatitis B virus and hepatitis C virus infection].

Authors:  S Kashiwagi
Journal:  Rinsho Byori       Date:  2000-01

2.  Sexual co-transmission of HIV, hepatitis B, and hepatitis C viruses.

Authors:  S Singh; D M Thappa; T J Jaisankar; S Sujatha
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

3.  Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen.

Authors:  H Marusawa; S Uemoto; M Hijikata; Y Ueda; K Tanaka; K Shimotohno; T Chiba
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

4.  On the role of sexual behavior in the spread of hepatitis B infection.

Authors:  W Szmuness; I Much; A M Prince; J H Hoofnagle; C E Cherubin; E J Harley; G H Block
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

5.  Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers.

Authors:  I Nishizono; S Iida; N Suzuki; H Kawada; H Murakami; Y Ashihara; M Okada
Journal:  Clin Chem       Date:  1991-09       Impact factor: 8.327

6.  Prevalence of human papillomavirus infection and its correlation with cervical lesions in commercial-sex workers in Japan.

Authors:  K Ishi; F Suzuki; A Saito; T Kubota
Journal:  J Obstet Gynaecol Res       Date:  2000-08       Impact factor: 1.730

7.  GB virus-C/hepatitis G virus infection in prostitutes: possible role of sexual transmission.

Authors:  J H Kao; W Chen; P J Chen; M Y Lai; R Y Lin; D S Chen
Journal:  J Med Virol       Date:  1997-08       Impact factor: 2.327

8.  Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services.

Authors:  R A Gunn; P J Murray; M L Ackers; W G Hardison; H S Margolis
Journal:  Sex Transm Dis       Date:  2001-03       Impact factor: 2.830

9.  Hepatitis B virus transmission between heterosexuals.

Authors:  M J Alter; J Ahtone; I Weisfuse; K Starko; T D Vacalis; J E Maynard
Journal:  JAMA       Date:  1986-09-12       Impact factor: 56.272

10.  A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army.

Authors:  L B Seeff; G W Beebe; J H Hoofnagle; J E Norman; Z Buskell-Bales; J G Waggoner; N Kaplowitz; R S Koff; J L Petrini; E R Schiff
Journal:  N Engl J Med       Date:  1987-04-16       Impact factor: 91.245

View more
  1 in total

Review 1.  Sex Worker Health Outcomes in High-Income Countries of Varied Regulatory Environments: A Systematic Review.

Authors:  Jessica McCann; Gemma Crawford; Jonathan Hallett
Journal:  Int J Environ Res Public Health       Date:  2021-04-09       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.